Host genetic factors in the clinical course of HIV-1 infection: Chemokines and chemokine receptors

Community Genetics

Volumn 5, Issue 2, 2002, Pages 88-101

  Van Rij, Ronald P ^a   Schuitemaker, Hanneke ^a  

^a CENTRAL LABORATORY   (Netherlands)

Author keywords

AIDS; CCR5; Chemokine receptor; CXCR4; HIV 1

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; INTERLEUKIN 10; INTERLEUKIN 4; RANTES; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE COURSE; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR GENE; REVIEW; SEROCONVERSION; VIRUS CELL INTERACTION; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036969199     PISSN: 14222795     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065169     Document Type: Review

References (147)

1. Hendriks JC, Medley GF, Van Griensven GJ, Coutinho RA, Heisterkamp SH, Van Druten HA: The treatment-free incubation period of AIDS in a cohort of homosexual men. AIDS 1993;7:231-239.
2. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE study, O'Brien SJ: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-1862.
3. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:1-20.
4. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber C-M, Saragosti S, Lapouméroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-725.
5. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
6. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger L, Kostrikis LG, Zhang L, Perelson AS, Ho DD: Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999;189:991-998.
7. Ogg GS, Jin X, Bonhoeffer S, Dunbar PD, Nowak M, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markovits M, Ho DD, Nixon DF, McMichael AJ: Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-2106.
8. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD: Temporal associations of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655.
9. Klein MR, Van Baalen CA, Holwerda AM, Kerkhof-Garde SR, Bende RJ, Keet IPM, Eeftinck Schattenkerk JKM, Osterhaus ADME, Schuitemaker H, Miedema F: Kinetics of Gag-specific CTL responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-1372.
10. Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J: Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med 1999;5:535-541.
11. Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, Deacon NJ, Sullivan JS: Immunological and virological status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 1999;340:1756-1757.
12. Blaak H, Brouwer M, Ran LJ, De Wolf F, Schuitemaker H: In vitro replication kinetics of HIV-1 variants in relation to viral load in long-term survivors of HIV-1 infection. J Infect Dis 1998;177:600-610.
13. Berger EA, Doms RW, Fenyo EM, Korber BTM, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA: A new classification for HIV-1. Nature 1998;391:240.
14. Koot M, Keet IPM, Vos AHV, De Goede REY, Roos MThL, Coutinho RA, Miedema F, Schellekens PThA, Tersmette M: Prognostic value of human immunodeficiency virus type 1 biological phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-688.
15. Connor RI, Mohri H, Cao Y, Ho DD: Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1 infected individuals. J Virol 1993;67:1772-1777.
16. Ward SG, Bacon K, Westwick J: Chemokines and T lymphocytes: More than an attraction. Immunity 1998;9:1-11.
17. Loetscher P, Moser B, Baggiolini M: Chemokines and their receptors in lymphocyte traffick and HIV infection. Adv Immunol 2000;74:127-180.
18. Cyster JG: Chemokines and cell migration in secondary lymphoid organs. Science 1999;286:2098-2102.
19. Van Rij RP, Blaak H, Visser JA, Brouwer M, Rientsma R, Broersen S, De Roda Husman AM, Schuitemaker H: Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. J Clin Invest 2000;160:1039-1052.
20. Blaak H, Van 't Wout AB, Brouwer M, Hooibrink B, Hovenkamp E, Schuitemaker H: In vivo HIV-1 infection of CD45RA+CD4+ T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4+ T cell decline. Proc Natl Acad Sci USA 2000;97:1269-1274.
21. Fouchier RAM, Brouwer M, Kootstra NA, Huisman JG, Schuitemaker H: HIV-1 macrophage-tropism is determined at multiple steps of the viral replication cycle. J Clin Invest 1994;94:1806-1814.
22. Zack JA, Haislip AM, Krogstad P, Chen ISY: Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992;66:1717-1725.
23. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
24. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, Vandevanter NL, Padian N, Braun JF, Kotler DP, Wolinsky SM, Koup RA: Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nat Med 1996;2:412-417.
25. Deng HK, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Suttons RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR: Identification of the major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-666.
26. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829-832.
27. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier J-L, Arenzana-Seisdedos F, Schwartz O, Heard J-M, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line adapted HIV-1. Nature 1996;382:833-835.
28. Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Sill A, Blattner WA, Cocchi F, Carlo DJ, DeVico AL, Gallo RC: Spontaneous and antigen-induced production of HIV-inhibitory β-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA 1999;96:11986-11991.
29. Cocchi F, DeVico AL, Yarchoan R, Redfield R, Cleghorn F, Blattner WA, Garzino-Demo A, Colobini-Hatch S, Margolis D, Gallo RC: Higher macrophage inflammatory protein (MIP)-1α and MIP-1β levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci USA 2000;97:13812-13817.
30. Paxton WA, Liu R, Kang S, Wu L, Gingeras TR, Landau NR, Mackay CR, Koup RA: Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: Association with low expression of CCR5 and high production of β-chemokines. Virology 1998;244:66-73.
31. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, Choe H, Sodroski J, Newman W, Koup RA, Mackay CR: CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997;185:1681-1691.
32. Pollack MS, Rich RR: The HLA complex and the pathogenesis of infectious diseases. J Infect Dis 1985;151:1-8.
33. Hill AVS: The immunogenetics of human infectious diseases. Annu Rev Immunol 1998;16:593-617.
34. Arnaiz-Villena A: MHC research: Fast forward. Immunol Today 1993;14:3-5.
35. Keet IPM, Klein MR, Just J, Kaslow RA: The role of host genetics in the natural history of HIV-1 infection: The needles in the haystack. AIDS 1996;10(suppl A):S59-S67.
36. Just JJ: Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome. A review of the literature examining associations with HLA. Hum Immunol 1995;44:156-169.
37. Roger M: Influence of host genes on HIV-1 disease progression. FASEB J 1998;12:625-632.
38. Michael NL: Host genetic influences on HIV-1 pathogenesis. Curr Opin Immunol 1999;11:466-474.
39. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SJ, Rinaldo C, Detels R, Blattner W, Phair JP, Erlich H, Mann DL: Influence of combinations of human major histocompatibility complex genes in the course of HIV-1 infection. Nat Med 1996;2:405-411.
40. Magierowska M, Theodorou I, Debre P, Sanson F, Autran B, Riviere Y, Charron D, French ALT and IMMUNOCO study groups, Costagliola D: Combined genotypes of CCR5, CCR2, SDF1 and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1 infected individuals. Blood 1999;93:936-941.
41. Klein MR, Van der Burg SH, Hovenkamp E, Holwerda AM, Drijfhout JW, Melief CJM, Miedema F: Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. J Gen Virol 1998;79:2191-2201.
42. Flores-Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, Leung JY, Uglialoro AM, Clavijo OP, Rosenberg ES, Kalams SA, Braun JD, Boswell SL, Walker BD, Goldfeld AE: Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci USA 2001;98:5140-5145.
43. Nelson GW, Kaslow R, Mann DL: Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection. Proc Natl Acad Sci USA 1997;94:9802-9807.
44. van Rij RP, Schuitemaker H: The role of HIV-1 biological phenotype and patient genotype in anti-retroviral treatment decisions. Curr Opin Anti-infect Invest Drugs 1999;1:155-165.
45. Hoffman TL, Doms RW: Chemokines and coreceptors in HIV/SIV-host interactions. AIDS 1998;12:S17-S26.
46. Paxton WA, Kang S, Koup RA: The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression. AIDS Res Hum Retroviruses 1998;14:S89-S91.
47. Ioannidis JPA, O'Brien TR, Rosenberg PS, Contopoulos-Ioannidis DG, Goedert JJ: Genetic effects on HIV disease progression. Nat Med 1998;4:536.
48. Ioannidis JPA, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, et al: Effects of CCR5 Δ32, CCR2 64I and SDF-1 3′A polymorphisms on HIV disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001;135:782-795.
49. Meyer L, Magierowska M, Hubert J-B, Rouzioux C, Deveau C, Sanson F, Debre P, Delfraissy J-F, Theodorou I, the SEROCO Study Group: Early protective effect of CCR5 Δ32 heterozygosity on HIV-1 disease progression: Relationship with viral load. AIDS 1997;11:F73-F78.
50. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, Koup RA: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-1243.
51. Schinkel J, Langendam M, Coutinho RA, Krol A, Brouwer M, Schuitemaker H: No evidence for an effect of the CCR5 Δ32/+ and the CCR2b 64I/+ mutations on human immunodeficiency virus type 1 (HIV-1) disease progression among HIV-1 infected injecting drug users. J Infect Dis 1999;179:825-831.
52. Wilkinson DA, Operskalski EA, Busch M, Mosley JW, Koup RA: A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS defining illness. J Infect Dis 1998;178:1163-1166.
53. Misrahi M, Teglas JP, N'Go M, Burgard M, Mayaux M-J, Rouzioux C, Delfraissy J-F, Blanche S: CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. JAMA 1998;279:277-280.
54. Buseyne F, Janvier G, Teglas JP, Ivanoff S, Burgard M, Bui E, Mayaux M-J, Blanche S, Rouzioux C, Riviere Y: Impact of heterozygosity for the chemokine receptor CCR5 32-bp deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age. J Infect Dis 1998;178:1019-1023.
55. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, Craig FE, O'Connell P, Tryon V, Clark RA, Dolan MJ, Ahuja SK: Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998;4:786-793.
56. Kostrikis LG, Huang Y, Moore JP, Wolinsky SM, Zhang L, Guo Y, Deutsch L, Phair J, Neumann AU, Ho DD: A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promotor mutation. Nat Med 1998;4:350-353.
57. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Multicenter AIDS Cohort Study, Murphy PM: CCR5 promotor polymorphism and HIV-1 disease progression. Lancet 1998;352:866-870.
58. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, Lee B, Doms RW, Margolick J, Buchbinder S, Goedert JJ, O'Brien TR, Hilgartner MW, Vlahov D, O'Brien SJ, Carrington M: Genetic acceleration of AIDS progression by a promotor variant of CCR5. Science 1998;282:1907-1911.
59. Carrington M, Dean M, Martin MP, O'Brien SJ: Genetics of HIV-1 infection: Chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Gen 1999;8:1939-1945.
60. Clegg AO, Ashton LJ, Biti RA, Badhwar P, Williamson P, Kaldor JM, Stewart GJ, Australian Long-term non-progressor study group: CCR5 promotor polymorphisms, CCR5 59029A and CCR5 59353C, are underrepresented in HIV-1-infected long-term non-progressors. AIDS 2000;14:103-108.
61. An P, Martin MP, Nelson GW, Carrington M, Smith MW, Gong K, Vlahov D, O'Brien SJ, Winkler CA: Influence of CCR5 promotor haplotypes on AIDS progression in African-Americans. AIDS 2000;14:2117-2122.
62. Ometto L, Bertorelle R, Mainardi M, Zanchetta M, Tognazzo S, Rampon O, Ruga E, Chieco-Bianchi L, De Rossi A: Polymorphisms in the CCR5 promotor region influence disease progression in perinatally human immunodeficiency virus type 1-infected children. J Infect Dis 2001;183:814-818.
63. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow R, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner MW, Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE study, O'Brien SJ: Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997;277:959-965.
64. Mariani R, Wong S, Mulder LCF, Wilkinson DA, Reinhart AL, LaRosa G, Nibbs R, O'Brien TR, Michael NL, Connor RI, MacDonald M, Busch M, Koup RA, Landau NR: CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. J Virol 1999;73:2450-2459.
65. Lee B, Doranz BJ, Rana S, Yi Y, Mellado M, Frade JMR, Martinez-A C, O'Brien SJ, Dean M, Collman RG, Doms RW: Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5 and CXCR4. J Virol 1998;72:7450-7458.
66. Sabbe R, Picchio GR, Pastore C, Chaloin O, Hartley O, Offord R, Mosier DE: Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression. J Virol 2001;75:661-671.
67. Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, de Ana AM, Martinez-A C: Chemokine control of HIV-1 infection. Nature 1999;400:723-724.
68. Van Rij RP, De Roda Husman AM, Brouwer M, Goudsmit J, Coutinho RA, Schuitemaker H: Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. J Infect Dis 1998;178:1806-1811.
69. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, French ALT and IMMUNOCO study groups, Delfraissy J-F, Seroco cohort, McDermott DH, Murphy PM, Debre P, Theodorou I, Combadiere C: Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000;287:2274-2277.
70. McDermott DH, Colla JS, Kleeberger CA, Plankey M, Rosenberg PS, Smith ED, Zimmerman PA, Combadiere C, Leitman SF, Kaslow RA, Goedert JJ, Berger EA, O'Brien TR, Murphy PM: Genetic Polymorphism in CX3CR1 and risk of HIV disease. Science 2000;290:2031.
71. Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, Xin X, Takamatsu JK, Saito H, Ishikawa Y, Akaza T, Juji T, Takebe Y, Ohishi T, Fukutake K, Maruyama Y, Yashiki S, Sonoda S, Nakamura T, Nagai Y, Iwamoto A, Shioda T: Polymorphism in RANTES chemokine promotor affects HIV-1 disease progression. Proc Natl Acad Sci USA 1999;96:4581-4585.
72. McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif FM, Ollier WER, Zimmerman PA, Boatin BA, Leitman SF, Detels R, Hajeer AH, Murphy PM: Chemokine RANTES promotor polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS cohort study. AIDS 2000;14:2671-2678.
73. Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, Plunkett BS, Freidhoff LR, Sengler C, Plitt JR, Schleimer RP, Caraballo L, Naidu RP, Levett PN, Beaty TH, Huang S-K: Atopic dermatitis is associated with a functional mutation in the promotor of the C-C chemokine RANTES. J Immunol 2000;164:1612-1616.
74. Winkler C, An P, Nelson G, Modi W, Wang L, Donfield S, Goedert JJ, Phair J, Vlahov D, O'Brien SJ: Interacting RANTES variants modulate HIV infection and progression (abstract 369). Keystone Symposia, HIV Pathogenesis 2001.
75. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D, Buchbinder S, Vittinghoff E, Goedert JJ, O'Brien TR, Jacobson LP, Detels R, Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair J, ALIVE, HGDS, MACS, MHCS, SFCC, O'Brien SJ: Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998;279:389-393.
76. Van Rij RP, Broersen S, Goudsmit J, Coutinho RA, Schuitemaker H: The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 1998;12:F85-F90.
77. Easterbrook PJ, Rostron T, Ives N, Troop M, Gazzard BG, Rowland-Jones SL: Chemokine receptor polymorphisms and human immunodeficiency virus disease progression. J Infect Dis 1999;180:1096-1105.
78. Balotta C, Bagnarelli P, Corvasce S, Mazzucchelli R, Colombo MC, Papagno L, Santambrogio S, Ridolfo AL, Violin M, Berlusconi A, Velleca R, Facchi G, Moroni M, Clementi M, Galli M, Resistant Hist Perspective Study Group: Identification of two distinct subsets of long-term nonprogressors with divergent viral activity by stromal-derived factor 1 chemokine gene polymorphism analysis. J Infect Dis 1999;180:285-289.
79. Brambilla A, Villa C, Rizzardi GP, Veglia F, Ghezzi S, Lazzarin A, Cusini M, Muratori S, Santagostino E, Gringeri A, Louie LG, Sheppard HW, Poli G, Michael NL, Pantaleo G, Vicenzi E: Shorter survival of SDF1-3′A/3′A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection. J Infect Dis 2000;182:311-315.
80. Schuitemaker H, Kootstra NA, Koppelman MHGM, Bruisten SM, Huisman HG, Tersmette M, Miedema F: Proliferation dependent HIV-1 infection of monocytes occurs during differentiation into macrophages. J Clin Invest 1992;89:1154-1160.
81. Valentin A, Lu W, Rosati M, Schneider R, Albert J, Karlsson A, Paulakis GN: Dual effect of interleukin 4 on HIV-1 expression: Implications for viral phenotypic switch and disease progression. Proc Natl Acad Sci USA 1998;95:8886-8891.
82. Wang J, Roderiquez G, Oravecz T, Norcross MA: Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression. J Virol 1998;72:7642-7647.
83. Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert JJ, O'Brien TR, Vlahov D, Buchbinder S, Giorgi J, Rinaldo C, Donfield S, Willoughby A, O'Brien SJ, Smith MW: Genetic restriction of HIV-1 pathogenesis to AIDS by promotor alleles of Il10. Proc Natl Acad Sci USA 2000;97:14467-14472.
84. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P: Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumato arthritis. Arthritis Rheum 1999;42:1101-1108.
85. Koot M, Vos AHV, Keet RPM, De Goede REY, Dercksen W, Terpstra FG, Coutinho RA, Miedema F, Tersmette M: HIV-1 biological phenotype in long term infected individuals, evaluated with an MT-2 cocultivation assay. AIDS 1992;6:49-54.
86. Richman DD, Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-974.
87. Fouchier RAM, Schuitemaker H: Molecular determinants of human immunodeficiency virus type 1 phenotype variability. Eur J Clin Invest 1996;26:175-185.
88. Kuiken CL, De Jong J-J, Baan E, Keulen W, Tersmette M, Goudsmit J: Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol 1992;66:4622-4627.
89. Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, Murphy PM, Jeang K-T: Selective CXCR4 antagonism by Tat: Implications for in vivo expansion of coreceptor usage by HIV-1. Proc Natl Acad Sci USA 2000;97:11466-11471.
90. Koot M, Van Leeuwen R, De Goede REY, Danner SA, Eeftink Schattenkerk JKM, Lange JMA, Tersmette M, Reiss P, Schuitemaker H: Conversion rate towards a syncytium inducing (SI) phenotype during different stages of HIV-1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999;179:254-258.
91. Nakayama EE, Hoshino Y, Xin X, Liu H, Goto M, Watanabe N, Taguchi H, Hitani A, Kawana-Tachikawa A, Fukushima M, Yamada K, Sugiura W, Oka S, Ajisawa A, Sato H, Takebe Y, Nakamura T, Nagai Y, Iwamoto A, Shioda T: Polymorphism in the Interleukin-4 promotor affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. J Virol 2000;74:5452-5459.
92. Vicenzi E, Ghezzi S, Brambilla A, Sheppard HW, Lazzarin A, Poli G, Michael NL: CCR2-64I polymorphism, syncytium-inducing human immunodeficiency virus strains and disease progression. J Infect Dis 2000;182:1578-1579.
93. Caceres CF, Van Griensven GJP: Male homosexual transmission of HIV-1. AIDS 1994;8:1051-1061.
94. Ahmad N: Maternal-fetal transmission of human immunodeficiency virus. J Biomed Sci 1996;3:238-250.
95. Busch MP, Operskalski EA, Mosley JW, Lee T-H, Henrard D, Herman S, Sachs DH, Harris M, Huang W, Stram DO, for the Transfusion Safety Study Group: Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. J Infect Dis 1996;174:26-33.
96. Van 't Wout AB, Koup RA, Paxton WA: HIV-1 Transmission; in Schuitemaker H, Miedema F (eds): AIDS pathogenesis. Dordrecht, Kluwer, 2000, pp 1-17.
97. Ometto L, Zanotto C, Maccabruni A, et al: Viral phenotype and host-cell susceptibility to HIV-1 infection as risk factors for mother-to-child HIV-1 transmission. AIDS 1995;9:427-434.
98. Blaak H, Van 't Wout AB, Brouwer M, Cornelissen M, Kootstra NA, Albrecht-van Lent N, Keet RPM, Goudsmit J, Coutinho RA, Schuitemaker H: Infectious cellular load in HIV-1-infected individuals and susceptibility of PBMC from their exposed partners to NSI HIV-1 as major determinants for HIV-1 transmission in homosexual couples. J Virol 1998;72:218-224.
99. Keet IPM, Krijnen P, Koot M, Lange JMA, Miedema F, Goudsmit J, Coutinho RA: Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993;7:51-57.
100. Fang G, Burger H, Grimson R, Tropper P, Nachman S, Mayers D, Weislow O, Moore R, Reyelt C, Hutcheon N, Baker D, Weiser B: Maternal plasma human immunodeficiency virus type 1 RNA level: A determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995;92:12100-12104.
101. Khouri YF, McIntosh K, Cavacini L, Posner M, Pagano M, Tuomala R: Vertical transmission of HIV-1. J Clin Invest 1995;95:732-737.
102. Dickover RE, Garratty EM, Herman SA, Sim M-S, Plaeger S, Boyer PJ, Keller M, Deveikis A, Stiehm ER, Bryson YJ: Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. JAMA 1996;275:599-605.
103. Gray RH, Wawe MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, Lutalo T, Li X, Vancott T, Quinn TC, the Rakay Project team: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1 discordant couples in Rakai, Uganda. Lancet 2001;357:1149-1153.
104. Aarons E, Fernandez M, Rees A, McClure M, Weber J: CC Chemokine receptor 5 genotypes and in vitro susceptibility to AIDS of a cohort of British HIV-exposed uninfected homosexual men. AIDS 1997;11:688-689.
105. Zamarchi R, Indraccolo S, Minuzzo S, Coppola V, Gringeri A, Santagostino E, Vicenzi E, De Silvestro G, Biagiotti R, Baldassarre C, Chieco-Bianchi L, Amadori A: Frequency of mutated CCR-5 allele (Δ32) among Italian healthy donors and individuals at risk of parenteral HIV infection. AIDS Res HumRetroviruses 1999;15:337-344.
106. Kupfer B, Kaiser R, Brackmann H-H, Effenberger W, Rockstroh JK, Matz B, Schneweis KE: Protection against parenteral HIV-1 infection by homozygous deletion in the C-C chemokine receptor 5 gene. AIDS 1999;13:1025-1028.
107. Salkowitz JR, Purvis SF, Meyerson H, Zimmerman P, O'Brien TR, Aledort L, Eyster ME, Hilgartner M, Kessler C, Konkle BA, White GC, Goedert JJ, Lederman MM: Characterization of high-risk HIV-1 seronegative hemophiliacs. Clin Immunol 2001;98:200-211.
108. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C, the SEROCO Study Group: HIV-1 infection in an individual homozygous for CCR5 Δ32. Lancet 1997;346:1219-1220.
109. O'Brien TR, Winkler C, Dean M, Nelson JA, Carrington M, Michael NL, White GC: HIV-1 infection in a man homozygous for CCR5 Δ32. Lancet 1997;349:1219.
110. Balotta C, Bagnarelli P, Violin M, Ridolfo AL, Zhou D, Berlusconi A, Corvasce S, Corbellino M, Clementi M, Clerici M, Moroni M, Galli M: Homozygous Δ32 deletion of the CCR5 chemokine receptor gene in an HIV-1 infected patient. AIDS 1997;11:F67-F71.
111. Biti R, French R, Young J, Bennetts B, Stewart G, Liang T: HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997;3:252-253.
112. Michael NL, Nelson JAE, Kewal Ramani VN, Chang G, O'Brien SJ, Mascola JR, Volsky B, Louder M, White II GC, Littman DR, Swanstrom R, O'Brien TR: Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 Δ32. J Virol 1998;72:6040-6047.
113. Sipsas NV, Kalams SA, Trocha A, He S, Blattner WA, Walker BD, Johnson RP: Identification of type-specific cytotoxic T lymphocytes responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1. J Clin Invest 1997;99:752-762.
114. Hoffman TL, MacGregor RR, Burger H, Mick R, Doms RW, Collman RG: CCR5 genotypes in sexually active couples discordant for human immunodeficiency virus type 1 infection status. J Infect Dis 1997;176:1093-1096.
115. Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbinder S, Koblin B, Seage GR, III: Homozygous and heterozygous CCR5-delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 2001;27:472-481.
116. Williams SB, Flanigan TP, Artenstein AW, VanCott TC, Smith D, Mayer K, Koup RA: CCR5 genotype and human immunodeficiency virus (HIV)-specific mucosal antibody in seronegative women at high risk for HIV infection. J Infect Dis 1999;179:1310-1311.
117. Kostrikis LG, Neumann AU, Thomson B, Korber BT, McHardy P, Karanicolas R, Deutsch L, Huang Y, Lew JF, McIntosh K, Pollack H, Borkowsky W, Spiegel HML, Palumbo P, Oleske J, Bardeguez A, Luzuriaga K, Sullivan J, Wolinsky SM, Koup RA, Ho DD, Moore JP: A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J Virol 1999;73:10264-10271.
118. Lockett SF, Alonso A, Wyld R, Martin MP, Robertson JR, Gore SM, Leen CLS, Brettle RP, Yirrell DL, Carrington M, Leigh-Brown AJ: Effect of chemokine receptor mutations on heterosexual human immunodeficiency virus transmission. J Infect Dis 1999;180:614-620.
119. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, Bizzini B, Gringeri A, Santagostino E, Rappaport J, Feldman M, O'Brien SJ, Burny A, Gallo RC: C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 1998;95:3857-3861.
120. John GC, Rousseau C, Dong T, Rowland-Jones S, Nduati R, Mbori Ngacha D, Rostron T, Kreiss JK, Richardson BA, Overbaugh J: Maternal SDF1 3′A polymorphism is associated with increased perinatal human immunodeficiency virus type 1 transmission. J Virol 2000;74:5736-5739.
121. Pastinen T, Liitsola K, Niini P, Salminen M, Syvanen AC: Contribution of the CCR5 and MBL genes to susceptibility to HIV type 1 infection in the finnish population. AIDS Res Hum Retroviruses 1998;14:695-698.
122. Garred P, Madsen HO, Balslev U, Hofmann B, Pedersen C, Gerstoft J, Svejgaard A: Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997;349:236-240.
123. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J: Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002;29:184-190.
124. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB: Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997;16:221-222.
125. Martinson JJ, Hong L, Karanicolas R, Moore JP, Kostrikis LG: Global distribution of the CCR2-64I/CCR5-59653T HIV-1 disease-protective haplotype. AIDS 2000;14:483-489.
126. Gonzalez E, Bamshad M, Sato N, Mummidi S, Dhanda R, Catano G, Cabrera S, McBride M, Cao X-H, Merrill G, O'Connell P, Bowden DW, Freedman BI, Anderson SA, Walter EA, Evans JS, Stephan KT, Clark RA, Tyagi S, Ahuja SS, Dolan MJ, Ahuja SK: Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci USA 1999;96:12004-12009.
127. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, Buchbinder S, Hoots K, O'Brien SJ: HLA and HIV-1:Heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999;283:1748-1752.
128. Paxton WA, Koup RA: Mechanisms of resistance to HIV infection. Springer Semin Immunopathol 1997;18:323-340.
129. Kaul R, Plummer FA, Kimani J, Dong T, Kiama P, Rostron T, Njagi E, MacDonald KS, Bwayo JJ, McMichael AJ, Rowland-Jones SL: HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000;164:1602-1611.
130. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW: A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors. Cell 1996;85:1149-1158.
131. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J: The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148.
132. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673.
133. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA: CC CKR5:A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-1958.
134. Rucker J, Edinger AL, Sharron M, Samson M, Lee B, Berson JF, Yi Y,
135. Horuk R, Hesselgesser J, Zhou Y, Faulds D, Halks-Miller M, Harvey S, Taub D, Samson M, Parmentier M, Rucker J, Doranz BJ, Doms RW: The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. J Biol Chem 1998;273:386-391.
136. Choe H, Farzan M, Konkel M, Martin K, Sun Y, Marcon L, Cayabyab M, Berman M, Dorf ME, Gerard N, Gerard C, Sodroski J: The orphan seven-transmembrane receptor Apj supports the entry of primary T-cell-line-tropic and dual tropic human immunodeficiency virus type 1. J Virol 1998;72:6113-6118.
137. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
138. Deng HK, Unutmaz D, KewalRamani VN, Littman DR: Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997;388:296-300.
139. Liao F, Alkhatib G, Peden KWC, Sharma G, Berger EA, Farber JM: STRL33, a novel chemokine receptor-like protein, functions as fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med 1997;185:2015-2023.
140. Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM: Identification of CX3CR1, a chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem 1998;273:23799-23804.
141. Farzan M, Choe H, Martin K, Marcon L, Hofmann W, Karlsson G, Sun Y, Barrett P, Marchand N, Sullivan N, Gerard N, Gerard C, Sodroski J: Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J Exp Med 1997;186:405-411.
142. Edinger AL, Hoffman TL, Sharron M, Lee B, Yi Y, Choe W, Kolson DL, Mitrovic B, Zhou Y, Faulds D, Collman R, Hesselgesser J, Horuk R, Doms RW: An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 1998;72:7934-7940.
143. Samson M, Edinger AL, Stordeur P, Rucker J, Verhasselt V, Sharron M, Govaerts C, Mollereau C, Vassart G, Doms RW, Parmentier M: ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur J Immunol 2000;28:1689-1700.
144. Owman C, Garzino-Demo A, Cocchi F, Popovic M, Sabirsh A, Gallo RC: The leucotriene B4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. Proc Natl Acad Sci USA 1998;95:9530-9534.
145. Pleskoff O, Treboute C, Brelot A, Heveker N, Seman M, Alizon M: Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science 1997;276:1874-1878.
146. Zlotnik A, Yoshie O: Chemokines: A new classification system and their role in immunity. Immunity 2000;12:121-127.
147. Blanpain C, Lee B, Tackoen M, Puffer B, Boom A, Libert F, Sharron M, Wittamer V, Vassart G, Doms RW, Parmentier M: Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood 2001;96:1638-1645.